Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma

Published:2006 Issue:8 Volume:107 Page:1793-1800
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Suppiah Revathi,Shaheen Philip E.,Elson Paul,Misbah Seema A.,Wood Laura,Motzer Robert J.,Negrier Slyvie,Andresen Steven W.,Bukowski Ronald M.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference46 articles.

1. Cancer Statistics, 2006

2. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

3. CYTOTOXIC CHEMOTHERAPY FOR ADVANCED RENAL CELL CARCINOMA

4. , , et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Presented at the American Society of Clinical Oncology; May 13–17, 2005; Orlando, FL.

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined score based on plasma fibrinogen and platelet-lymphocyte ratio as a prognostic biomarker in esophageal squamous cell carcinoma;BMC Cancer;2024-02-22

2. Platelet Contributions to the (Pre)metastatic Tumor Microenvironment;Seminars in Thrombosis and Hemostasis;2023-10-13

3. Prostate cancer cell-platelet bidirectional signaling promotes calcium mobilization, invasion and apoptotic resistance via distinct receptor-ligand pairs;Scientific Reports;2023-02-17

4. Platelet detection as a new liquid biopsy tool for human cancers;Frontiers in Oncology;2022-09-14

5. Promising Biomarkers in Renal Cell Carcinoma;Société Internationale d’Urologie Journal;2021-01-18